

GAI 1617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Garver et al.

Appln. No. 09/359,593

Filed: July 23, 1999

For: CONTROLLED RELEASE OF
BIOACTIVE SUBSTANCES



Art Unit: 1617

Examiner: To Be Assigned

Docket No.: JHV-009.01

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Box IDS, the Assistant Commissioner for Patents, Washington, D.C. 20231 on June 29, 2000.

Eugene Coker
Eugene Coker

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Box IDS
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), (c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the issuance of a first Office Action in the application. Applicants submit that the items of information contained in this information disclosure statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Copies of the items of information are attached.

Applicants respectfully request that the Examiner consider the listed items and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed items are material or constitute "prior art." If the Examiner applies any of the items as prior art against any claim in the application and Applicants determine that such item or items do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such items.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed items, should the items be applied against the claims of the present Application.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Account No. 06-1448.

Should there be any questions after reviewing these papers, the Examiner is invited to contact the undersigned at (617) 832-1169.

Respectfully submitted,

FOLEY, HOAG & ELIOT LLP



Kingsley L. Taft
Reg. No. 43,946

June 29, 2000

Date

Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170